Pulmonary hypertension and renal dysfunction: a narrative review
By: Andrei Neagu and Miron Alexandru Bogdan
References
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International. 2024;105(4S): S117-S314. doi:10.1016/j.kint.2023.10.018
- Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11): 1157-1172. doi:10.1161/CIRCULATIONAHA.120.050686
- Zeder K, Siew ED, Kovacs G, Brittain EL, Maron BA. Pulmonary hypertension and chronic kidney disease: prevalence, pathophysiology and outcomes. Nature Reviews Nephrology. 2024;20(11): 742-754. doi:10.1038/s41581-024-00857-7
- Sise ME, Courtwright AM, Channick RN. Pulmonary hypertension in patients with chronic and end-stage kidney disease. Kidney International. 2013;84(4): 682-692. doi:10.1038/ki.2013.186
- Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38): 3618-3731. doi:10.1093/eurheartj/ehac237
- Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal. 2023;61(1): 2200879. doi:10.1183/13993003.00879-2022
- Kovacs G, Bartolome S, Denton CP, Gatzoulis MA, Gu S, Khanna D, et al. Definition, classification and diagnosis of pulmonary hypertension. European Respiratory Journal. 2024;64(4): 2401324. doi:10.1183/13993003.01324-2024
- Ruge M, Pancio G, Mehrotra P, Marhefka G. Accuracy of right atrial pressure estimation by transthoracic echocardiography. European Heart Journal. 2024;45(Suppl 1): ehae666.094. doi:10.1093/eurheartj/ehae666.094
- Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension. Chest. 2011;139(5): 988-993. doi:10.1378/chest.10-1269
- Tang M, Batty JA, Lin C, Fan X, Chan KE, Kalim S. Pulmonary hypertension, mortality, and cardiovascular disease in CKD and ESRD patients: a systematic review and meta-analysis. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation. 2018;72(1): 75-83. doi:10.1053/j.ajkd.2017.11.018
- Greiner S, Jud A, Aurich M, Hess A, Hilbel T, Hardt S, et al. Reliability of noninvasive assessment of systolic pulmonary artery pressure by Doppler echocardiography compared to right heart catheterization: analysis in a large patient population. Journal of the American Heart Association. 2014;3(4): e001103. doi:10.1161/JAHA.114.001103
- Edmonston DL, Parikh KS, Rajagopal S, Shaw LK, Abraham D, Grabner A, et al. Pulmonary hypertension subtypes and mortality in CKD. American Journal of Kidney Diseases. 2020;75(5): 713-724. doi:10.1053/j.ajkd.2019.08.027
- Navaneethan SD, Wehbe E, Heresi GA, Gaur V, Minai OA, Arrigain S, et al. Presence and outcomes of kidney disease in patients with pulmonary hypertension. Clinical Journal of the American Society of Nephrology (Wolters Kluwer Health). 2014;9(5): 855-863. doi:10.2215/CJN.10191013
- Bolignano D, Pisano A, Coppolino G, Tripepi GL, D’Arrigo G. Pulmonary hypertension predicts adverse outcomes in renal patients: a systematic review and meta-analysis. Therapeutic Apheresis and Dialysis. 2019;23(4): 369-384. doi:10.1111/1744-9987.12777
- Agarwal R. Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrology Dialysis Transplantation. 2012;27(10): 3908-3914. doi:10.1093/ndt/gfr661
- Yigla M, Nakhoul F, Sabag A, Tov N, Gorevich B, Abassi Z, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest. 2003;123(5): 1577-1582. doi:10.1378/chest.123.5.1577
- Li Z, Liang X, Liu S, Ye Z, Chen Y, Wang W, et al. Pulmonary hypertension: epidemiology in different CKD stages and its association with cardiovascular morbidity. Plos One. 2014;9(12): e114392. doi:10.1371/journal.pone.0114392
- Leuchte HH, El Nounou M, Tuerpe JC, Hartmann B, Baumgartner RA, Vogeser M, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest. 2007;131(2): 402-409. doi:10.1378/chest.06-1758
- Shah SJ, Thenappan T, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation. 2008;117(19): 2475-2483. doi:10.1161/CIRCULATIONAHA.107.719500
- Pabst S, Hammerstingl C, Hundt F, Gerhardt T, Grohé C, Nickenig G, et al. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. Plos One. 2012;7(4): e35310. doi:10.1371/journal.pone.0035310
- O’Leary JM, Assad TR, Xu M, Birdwell KA, Farber-Eger E, Wells QS, et al. Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes. Pulmonary Circulation. 2017;7(3): 674-683. doi:10.1177/2045893217716108
- Bitker L, Sens F, Payet C, Turquier S, Duclos A, Cottin V, et al. Presence of kidney disease as an outcome predictor in patients with pulmonary arterial hypertension. American Journal of Nephrology. 2018;47(2): 134-143. doi:10.1159/000487198
- Chakinala MM, Coyne DW, Benza RL, Frost AE, McGoon MD, Hartline BK, et al. Impact of declining renal function on outcomes in pulmonary arterial hypertension: a REVEAL registry analysis. The Journal of Heart and Lung Transplantation. 2018;37(6): 696-705. doi:10.1016/j.healun.2017.10.028
- Nickel NP, de Jesus Perez VA, Zamanian RT, Fessel JP, Cogan JD, Hamid R, et al. Low-grade albuminuria in pulmonary arterial hypertension. Pulmonary Circulation. 2019;9(2): 1-9. doi:10.1177/2045894018824564
- Edmonston DL, Rajagopal S, Wolf M. Echocardiography to screen for pulmonary hypertension in CKD. Kidney International Reports. 2020;5(12): 2275-2283. doi:10.1016/j.ekir.2020.09.033
- Meservey A, Al-Naamani N, Minhas J, Fritz JS, Appleby D, Baudry G, et al. Renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an individual participant data meta-analysis. European Respiratory Journal. 2025;66(2): 2402400. doi:10.1183/13993003.02400-2024
- Simmonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology. 2009;54(1 Suppl): S43-S54. doi:10.1016/j.jacc.2009.04.012
- Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T. State-of-the-art evidence in the treatment of systemic sclerosis. Nature Reviews Rheumatology. 2023;19(4): 212-226. doi:10.1038/s41584-023-00909-5
- Kronbichler A, Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC Medicine. 2013;11: 95. doi:10.1186/1741-7015-11-95
- Rossing P, Hansen TW, Kümler T. Cardiovascular and non-renal complications of chronic kidney disease: managing risk. Diabetes, Obesity & Metabolism. 2024;26(Suppl 6): 13-21. doi:10.1111/dom.15747
- Pelaia C, Pastori D, Armentaro G, Miceli S, Cassano V, Barbara K, et al. Predictors of renal function worsening in patients with chronic obstructive pulmonary disease (COPD): a multicenter observational study. Nutrients. 2021;13(8): 2811. doi:10.3390/nu13082811
- Kuma A, Kato A. Lifestyle-related risk factors for the incidence and progression of chronic kidney disease in the healthy young and middle-aged population. Nutrients. 2022;14(18): 3787. doi:10.3390/nu14183787
- Mallamaci F, Tripepi G. Risk factors of chronic kidney disease progression: between old and new concepts. Journal of Clinical Medicine. 2024;13(3): 678. doi:10.3390/jcm13030678
- Christiansen CF, Schmidt M, Lamberg AL, Horváth-Puhó E, Baron JA, Jespersen B, et al. Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study. Journal of Thrombosis and Haemostasis: JTH. 2014;12(9): 1449-1454. doi:10.1111/jth.12652
- Mahmoodi BK, Gansevoort RT, Næss IA, Lutsey PL, Brakkan SK, Veeger NJ, et al. Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts. Circulation. 2012;126(16): 1964-1971. doi:10.1161/CIRCULATIONAHA.112.113944
- Wattanakit K, Cushman M, Stehman-Breen C. Chronic kidney disease increases risk for venous thromboembolism. Journal of Vascular Surgery. 2009;49: 273. doi:10.1016/j.jvs.2008.11.117
- Yigla M, Dabbah S, Azzam ZS, Rubin AH, Reisner SA. Background diseases in 671 patients with moderate to severe pulmonary hypertension. The Israel Medical Association Journal. 2000;2: 684-689. PMID: 11062769.
- Pinter J, Chazot C, Stuard S, Moissl U, Canaud B. Sodium, volume and pressure control in haemodialysis patients for improved cardiovascular outcomes. Nephrology Dialysis Transplantation. 2020;35(Suppl 2): ii23-ii30. doi:10.1093/ndt/gfaa017
- Walther CP, Nambi V, Hanania NA, Navaneethan SD. Diagnosis and management of pulmonary hypertension in patients with CKD. American Journal of Kidney Diseases. 2020;75(6): 935-945. doi:10.1053/j.ajkd.2019.12.005
- Kaiser R, Seiler S, Held M, Bals R, Wilkens H. Prognostic impact of renal function in precapillary pulmonary hypertension. Journal of Internal Medicine. 2014;275(2): 116-126. doi:10.1111/joim.12131
- Guignabert C, Aman J, Bonnet S, Dorfmüller P, Olschewski AJ, Pullamsetti S, et al. Pathology and pathobiology of pulmonary hypertension: current insights and future directions. European Respiratory Journal. 2024;64(4): 2401095. doi:10.1183/13993003.01095-2024
- Chin KM, Gaine SP, Gerges C, Jing ZC, Mathai SC, Tamura Y, et al. Treatment algorithm for pulmonary arterial hypertension. European Respiratory Journal. 2024;64(4): 2401325. doi:10.1183/13993003.01325-2024
- Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney International. 2014;86(5): 896-904. doi:10.1038/ki.2014.143
- González-Rodríguez L, Martí-Antonio M, Mota-Zamorano S, Chicharro C, Cancho B, Luna E, et al. Endothelin-1 as dual marker for renal function decline and associated cardiovascular complications in patients with chronic kidney disease. European Journal of Internal Medicine. 2026;144: 106542. doi:10.1016/j.ejim.2025.106542
- Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: regulation and action. Pharmacological Research: the Official Journal of the Italian Pharmacological Society. 2009;60(6): 448-460. doi:10.1016/j.phrs.2009.08.002
- Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O’Hara B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Natural Medicines. 2007;13(2): 198-203. doi:10.1038/nm1543
- Kielstein JT, Bode-Böger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(7): 1414-1418. doi:10.1161/01.ATV.0000168414.06853.f0
- Matsuguma K, Ueda S, Yamagishi S, Matsumoto Y, Kaneyuki U, Shibata R, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. Journal of the American Society of Nephrology. 2006;17(8): 2176-2183. doi:10.1681/ASN.2005121379
- Xiao S, Wagner L, Schmidt RJ, Baylis C. Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney International. 2001;59(4): 1466-1472. doi:10.1046/j.1523-1755.2001.0590041466.x
- Lu T-M, Chung M-Y, Lin C-C, Hsu CP, Lin SJ. Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease. Clinical Journal of the American Society of Nephrology. 2011;6(7): 1566-1572. doi:10.2215/CJN.08490910
- Muñoz-Durango N, Fuentes CA, Castillo AE, González-Gómez LM, Vecchiola A, Fardella CE, et al. Role of the renin-angiotensin-aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in end-organ damage during arterial hypertension. International Journal of Molecular Sciences. 2016;17(7): 797. doi:10.3390/ijms17070797
- Ripley E. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease. American Heart Journal. 2009;157(6 Suppl): S7-S16. doi:10.1016/j.ahj.2009.04.008
- de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, François C, et al. Dysregulated renin–angiotensin–aldosterone system contributes to pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 2012;186(8): 780-789. doi:10.1164/rccm.201203-0411OC
- Ma Z, Viswanathan G, Sellig M, Jassal C, Choi I, Garikipati A, et al. β-arrestin-mediated angiotensin II type 1 receptor activation promotes pulmonary vascular remodeling in pulmonary hypertension. JACC Basic to Translational Science. 2021;6(11): 854-869. doi:10.1016/j.jacbts.2021.09.006
- Lahm T, Hess E, Barón AE, Maddox TM, Plomondon ME, Choudhary G, et al. Renin-angiotensin-aldosterone system inhibitor use and mortality in pulmonary hypertension. Chest. 2021;159(4): 1586-1597. doi:10.1016/j.chest.2020.09.258
- Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. Journal of the American Society of Nephrology. 2005;16(7): 2205-2215. doi:10.1681/ASN.2005010052
- Courbebaisse M, Lanske B. Biology of fibroblast growth factor 23: from physiology to pathology. Cold Spring Harbor Perspectives in Medicine. 2018;8(5): a031260. doi:10.1101/cshperspect.a031260
- Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney International. 2011;79(12): 1370-1378. doi:10.1038/ki.2011.47
- Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305(23): 2432. doi:10.1001/jama.2011.826
- Komaba H, Fukagawa M. The role of FGF23 in CKD—with or without Klotho. Nature Reviews Nephrology. 2012;8(8): 484-490. doi:10.1038/nrneph.2012.116
- Miri M, Ahmadi M, Hatami M. Correlation between fibroblast growth factor-23 and pulmonary arterial hypertension in hemodialysis patients. Iranian Journal of Kidney Diseases. 2021;15(4): 300-305. doi:10.52547/ijkd.5940
- Widmann L, Keranov S, Jafari L, Liebetrau C, Keller T, Troidl C, et al. Fibroblast growth factor 23 as a biomarker of right ventricular dysfunction in pulmonary hypertension. Clinical Research in Cardiology. 2023;112(10): 1382-1393. doi:10.1007/s00392-023-02162-y
- Kanbay M, Mutlu A, Bakir CN, Peltek IB, Canbaz AA, Díaz Tocados JM, et al. Klotho in pregnancy and intrauterine development—potential clinical implications: a review from the European Renal Association CKD-MBD Working Group. Nephrology Dialysis Transplantation. 2024;39(10): 1574-1582. doi:10.1093/ndt/gfae066
- Martín-Vírgala J, Martín-Carro B, Fernández-Villabrille S, Ruiz-Torres MP, Gómez-Alonso C, Rodríguez-García M, et al. Soluble Klotho, a potential biomarker of chronic kidney disease-mineral bone disorders involved in healthy ageing: lights and shadows. International Journal of Molecular Sciences. 2024;25(3): 1843. doi:10.3390/ijms25031843
- Hu MC, Shi M, Gillings N, Flores B, Takahashi M, Kuro-O M, et al. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy. Kidney International. 2017;91(5): 1104-1114. doi:10.1016/j.kint.2016.10.034
- Abraham CR, Li A. Aging-suppressor Klotho: prospects in diagnostics and therapeutics. Ageing Research Reviews. 2022;82: 101766. doi:10.1016/j.arr.2022.101766
- Varshney R, Ali Q, Wu C, Sun Z. Monocrotaline-induced pulmonary hypertension involves downregulation of antiaging protein Klotho and eNOS activity. Hypertension Dallas. 2016;68(5): 1255-1263. doi:10.1161/HYPERTENSIONAHA.116.08184
- Batlahally S, Franklin A, Damianos A, Huang J, Chen P, Sharma M, et al. Soluble Klotho, a biomarker and therapeutic strategy to reduce bronchopulmonary dysplasia and pulmonary hypertension in preterm infants. Scientific Reports. 2020;10(1): 12368. doi:10.1038/s41598-020-69296-1
- De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. Journal of the American Society of Nephrology. 2002;13(11): 2762-2769. doi:10.1097/01.ASN.0000034202.91413.EB
- Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney International. 2007;71(1): 31-38. doi:10.1038/sj.ki.5002009
- Geng S, Kuang Z, Peissig PL, Page D, Maursetter L, Hansen KE. Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease. Osteoporosis International. 2019;30(10): 2019-2025. doi:10.1007/s00198-019-05033-3
- Joki Y, Konishi H, Takasu K, Kastuumi G, Yoshida Y, Furihata T, et al. Parathyroid hormone exacerbates pulmonary hypertension via parathyroid hormone receptors on pulmonary artery smooth muscle cells. European Heart Journal. 2024;45(Suppl1): ehae666.3878. doi:10.1093/eurheartj/ehae666.3878
- Stern AB, Klemmer PJ. High-output heart failure secondary to arteriovenous fistula. Hemodialysis International. 2011;15(1): 104-107. doi:10.1111/j.1542-4758.2010.00518.x
- Basile C, Lomonte C, Vernaglione L, Casucci F, Antonelli M, Losurdo N. The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. Nephrology Dialysis Transplantation. 2007;23(1): 282-287. doi:10.1093/ndt/gfm549
- Kim Y, Kim JH, Woo J, Choi O, Lee M, Choi S. Hemodynamic adaptation and cardiac effects of high-flow arteriovenous access in hemodialysis patients: a prospective study. Journal of Clinical Medicine. 2025;14(13): 4556. doi:10.3390/jcm14134556
- Valerianova A, Malik J, Janeckova J, Kovarova L, Tuka V, Trachta P, et al. Reduction of arteriovenous access blood flow leads to biventricular unloading in haemodialysis patients. International Journal of Cardiology. 2021;334: 148-153. doi:10.1016/j.ijcard.2021.04.027
- Nguyen MC, Po-Yu Chiang T, Massie AB, Bae S, Motter JD, Brennan DC, et al. Kidney transplantation confers survival benefit for candidates with pulmonary hypertension. Transplant Direct. 2021;7(8): e738. doi:10.1097/TXD.0000000000001191
- Scalia IG, Farina JM, Pietri MP, Ali NB, Abbas MT, Awad K, et al. Association of pulmonary hypertension with outcomes in kidney transplant recipients. Kidney International Reports. 2025;10(7): 2394-2404. doi:10.1016/j.ekir.2025.04.058
- Zeder K, Kundu S, Siew ED, Annis JS, Lee LY, Garry J, et al. Longitudinal pulmonary arterial pressure trajectories and clinical outcome in kidney transplantation patients. Chest. 2025;168(5): 1200-1214. doi:10.1016/j.chest.2025.05.024
Language: English, Romanian
Page range: 83 - 93
Published on: Aug 18, 2026
Published by: Romanian Society of Pneumology
In partnership with: Paradigm Publishing Services
Publication frequency: Volume open
Related subjects:
© 2026 Andrei Neagu, Miron Alexandru Bogdan, published by Romanian Society of Pneumology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.